Prostate cancer: Early enzalutamide substantially improves time to progression and overall survival when added to standard mHSPC therapy (testosterone suppression ± docetaxel)

An interim analysis of the international randomised, phase 3 ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide along with the standard-of-care treatment were alive after 3 years...

Post-study immunotherapy confounds primary survival outcome

An exploratory analysis of the phase 3 MYSTIC trial suggests that the high rate of subsequent post-study immunotherapy received by patients with metastatic non-small cell lung cancer (NSCLC) who previously received chemotherapy, confounded the primary overall survival (OS) outcome. Durvalumab...

Head-to-head comparison of two ALK inhibitors

Brigatinib showed a statistically and clinically relevant improvement in PFS vs crizotinib in patients with anaplastic lymphoma kinase (ALK) inhibitor-naïve, ALK-positive non-small cell lung cancer (NSCLC). This was the result of the first interim analysis from the ALTA-1L study comparing the...